デフォルト表紙
市場調査レポート
商品コード
1069318

イソトレチノイン薬の世界市場-2027年までの予測

Isotretinoin Drugs Market - Forecast till 2027

出版日: | 発行: Market Research Future | ページ情報: 英文 115 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
イソトレチノイン薬の世界市場-2027年までの予測
出版日: 2022年03月28日
発行: Market Research Future
ページ情報: 英文 115 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のイソトレチノイン薬の市場規模は、予測期間中に4.68%の著しいCAGRで拡大し、2027年末には16億5,240万米ドルを超えると予測されています。

当レポートでは、世界のイソトレチノイン薬市場について調査し、市場の概要とともに、形態別、適応別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査手法

第4章 市場力学

  • 概要
  • 促進要因
    • 十代の若者と若い成人の間でのざ瘡の有病率の上昇
    • 神経芽細胞腫の発生率の上昇
  • 抑制要因
    • 薬物の副作用に関する懸念
  • 市場機会
    • 重度の難治性結節型ざ瘡治療のための新しい微粉末化製剤の導入

第5章 市場要因分析

  • バリューチェーン分析
  • ポーターのファイブフォースモデル
  • イソトレチノイン薬市場に対するCOVID-19の影響
    • サプライチェーンへの影響
    • イソトレチノイン薬市場への影響
    • ヘルスケアと医療費への影響
  • イソトレチノインカプセルの適応外使用
  • 処方された人員と投与量に関する適応別分析

第6章 世界のイソトレチノイン薬市場、形態別

  • 概要
  • カプセル
  • 注射

第7章 世界のイソトレチノイン薬市場、適応別

  • 概要
  • 重度のざ瘡
  • 扁平上皮癌
  • 皮膚T細胞リンパ腫
  • 神経芽細胞腫
  • 道化師様魚鱗癬
  • 色素性乾皮症
  • 進行性骨化性線維異形成症
  • その他

第8章 世界のイソトレチノイン薬市場、流通チャネル別

  • 概要
  • 院内薬局
  • 小売薬局
  • オンライン薬局

第9章 世界のイソトレチノイン薬市場、地域別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • スペイン
    • ウクライナ
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他
  • その他の地域
    • 中東
    • アフリカ
    • ラテンアメリカ

第10章 競合情勢

  • 概要
  • 競合ベンチマーキング
  • 世界のイソトレチノイン薬市場における主要な成長戦略
  • 世界のイソトレチノイン薬市場の開発件数における主要企業
  • 主要な開発分析
  • 主な発展と成長戦略
  • 財務マトリクス

第11章 企業プロファイル

  • DOUGLAS PHARMACEUTICALS LIMITED
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • AKORN OPERATING COMPANY LLC
  • DR. REDDY'S LABORATORIES LTD
  • F. HOFFMAN LA ROCHE LTD
  • MYLAN NV
  • SUN PHARMACEUTICALS
  • CIPHER PHARMACEUTICALS INC.
  • GLAXOSMITHKLINE PLC
  • CHONGQING HUAPONT
  • CATALENT PHARMA SOLUTIONS

第12章 付録

  • 参考文献
  • 関連レポート
図表

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 4 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR CAPSULE, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 5 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR INJECTION, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 6 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 7 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR SEVERE ACNE, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 8 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 9 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 10 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR NEUROBLASTOMA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 11 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR HARLEQUIN ICHTHYOSIS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 12 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR XERODERMA PIGMENTOSUM, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 13 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 14 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR OTHERS, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 15 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 16 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 17 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 18 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 19 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 20 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 21 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 22 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 23 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 24 US: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 25 US: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 26 US: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 27 CANADA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 28 CANADA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 29 CANADA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 30 EUROPE: ISOTRETINOIN DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 31 EUROPE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 32 EUROPE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 33 EUROPE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 34 GERMANY: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 35 GERMANY: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 36 GERMANY: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 37 FRANCE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 38 FRANCE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 39 FRANCE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 40 UK: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 41 UK: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 42 UK: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 43 ITALY: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 44 ITALY: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 45 ITALY: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 46 RUSSIA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 47 RUSSIA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 48 RUSSIA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 49 SPAIN: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 50 SPAIN: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 51 SPAIN: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 52 UKRAINE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 53 UKRAINE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 54 UKRAINE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 55 REST OF EUROPE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 56 REST OF EUROPE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 57 REST OF EUROPE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 58 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
  • TABLE 59 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 60 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 61 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 62 CHINA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 63 CHINA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 64 CHINA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 65 INDIA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 66 INDIA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 67 INDIA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 68 JAPAN: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 69 JAPAN: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 70 JAPAN: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 71 SOUTH KOREA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 72 SOUTH KOREA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 73 SOUTH KOREA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 74 AUSTRALIA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 75 AUSTRALIA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 76 AUSTRALIA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 77 REST OF ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 78 REST OF ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 79 REST OF ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 80 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)
  • TABLE 81 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 82 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 83 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 84 MIDDLE EAST: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 85 MIDDLE EAST: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 86 MIDDLE EAST: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 87 AFRICA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 88 AFRICA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 89 AFRICA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 90 LATIN AMERICA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
  • TABLE 91 LATIN AMERICA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
  • TABLE 92 LATIN AMERICA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
  • TABLE 93 MAJOR PLAYERS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
  • TABLE 94 MOST ACTIVE PLAYER IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
  • TABLE 95 PRODUCT LAUNCHES/PRODUCT APPROVALS
  • TABLE 96 EXPANSIONS
  • TABLE 97 DOUGLAS PHARMACEUTICALS LIMITED: PRODUCTS/SERVICES OFFERED
  • TABLE 98 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 99 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
  • TABLE 100 AKORN OPERATING COMPANY LLC: PRODUCTS/SERVICES OFFERED
  • TABLE 101 DR. REDDY'S LABORATORIES LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 102 DR. REDDY'S LABORATORIES LTD: KEY DEVELOPMENTS
  • TABLE 103 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
  • TABLE 104 MYLAN NV: PRODUCTS/SERVICES OFFERED
  • TABLE 105 SUN PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 106 SUN PHARMACEUTICALS: KEY DEVELOPMENTS
  • TABLE 107 CIPHER PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 108 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
  • TABLE 109 CHONGQING HUAPONT: PRODUCTS OFFERED
  • TABLE 110 CATALENT PHARMA SOLUTIONS: PRODUCTS OFFERED
  • TABLE 111 CATALENT PHARMA SOLUTIONS: KEY DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL ISOTRETINOIN DRUGS MARKET STRUCTURE
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: GLOBAL ISOTRETINOIN DRUGS MARKET
  • FIGURE 5 DRIVERS: IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT: IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL ISOTRETINOIN DRUGS MARKET
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ISOTRETINOIN DRUGS MARKET
  • FIGURE 9 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY FORM, 2020 & 2027 (USD MILLION)
  • FIGURE 10 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2020 & 2027 (USD MILLION)
  • FIGURE 11 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020 & 2027 (USD MILLION)
  • FIGURE 12 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY REGION 2020 & 2027 (USD MILLION)
  • FIGURE 13 GLOBAL: ISOTRETINOIN DRUGS MARKET SHARE (%), BY REGION, 2020
  • FIGURE 14 EUROPE: ISOTRETINOIN DRUGS MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 15 EUROPE: ISOTRETINOIN DRUGS MARKET SHARE (%), BY COUNTRY, 2020
  • FIGURE 16 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET SHARE (%), BY REGION, 2020
  • FIGURE 17 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET SHARE (%), BY REGION 2020
  • FIGURE 18 MAJOR MANUFACTURERS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
  • FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
  • FIGURE 21 GLOBAL ISOTRETINOIN DRUGS MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 22 SALES, (USD MILLION), 2020
  • FIGURE 23 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020
  • FIGURE 24 DOUGLAS PHARMACEUTICALS LIMITED: SWOT ANALYSIS
  • FIGURE 25 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 26 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
  • FIGURE 27 AKORN OPERATING COMPANY LLC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 DR. REDDY'S LABORATORIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 DR. REDDY'S LABORATORIES LTD: SWOT ANALYSIS
  • FIGURE 30 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS
  • FIGURE 32 MYLAN NV: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 FINANCIAL OVERVIEW
  • FIGURE 34 SUN PHARMACEUTICALS: SWOT ANALYSIS
  • FIGURE 35 CIPHER PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 36 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 37 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
  • FIGURE 38 CATALENT PARMA SOLUTIONS: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/HC/2418-CR

Market Forecast

The global isotretinoin drugs market is anticipated to register a significant CAGR of 4.68% during the forecast period to surpass a market value of USD 1,652.40 million by the end of 2027.

The global isotretinoin drug market is expected to register a notable market expansion during the review period owing to the growing incidences of acne among people and neuroblastoma. Additionally, the emergence of micronized formation for serious recalcitrant nodular acne cure creates lucrative scope for the global market. Besides, the concerns relating to drug side-effects are anticipated to hamper the global market growth.

The admission of isotretinoin drug presents wellbeing gambles among pregnant ladies. The medication can cause a few birth deformities, for example, the congenital fissure and inherent heart deserts among others. Likewise, unnatural birth cycle and stillbirth are a portion of the significant incidental effects set off by the utilization of the isotretinoin drug. Different confusions impeding the isotretinoin drugs market incorporate dry skin, seriously dried out lips, nosebleeds, dry and disturbed eyes, and dry mouth. The medicine was additionally answered to cause transitory secondary effects like deteriorating of skin inflammation, night visual impairment, diminishing hair, and muscle or joint agony. Also, rashes, stomach issues, and unfortunate cholesterol levels are the interesting conceivable aftereffects that singular encounters during the admission of isotretinoin drugs.

Market Segmentation

The Global Isotretinoin Drugs Market is classified based on Form, indication, distribution channel, and others. By form segment, the global market has been bifurcated into Injection and Capsule.

Based on Indication the market is classified into Severe acne, Squamous cell carcinoma, cutaneous T-cell lymphoma, Neuroblastoma, Harlequin ichthyosis, Xeroderma pigmentosum, and Fibrodysplasia ossificans progressive.

The Distribution Channel divides the market into three main types namely Hospital pharmacies, Retail Pharmacies, and Online pharmacies.

Region-Specific Analysis

North America represented a market size of USD 468.76 million of every 2020 and is relied upon to show a 5.06% CAGR during the review time frame. The isotretinoin drugs market is filling in the area because of created medical care framework, good unofficial laws, the rising pervasiveness of different skin issues, hereditary issues, and malignant growth, as well as expanded R&D venture.

The Asia-Pacific isotretinoin drugs market is relied upon to develop at a CAGR of 6.18% somewhere in the range of 2021 and 2027. The presence of a few market players in the region, for example, Sun Pharma organization (India) and Dr. Reddy's Laboratories Ltd (India), is driving the territorial market development. Moreover, because of the expansion in financing from financial backers, the utilization of isotretinoin is ceaselessly ascending among the clients in more burdened regions, with Asia seeing a relatively higher expansion being used.

Major Players

The key players in the global isotretinoin drugs market are Teva Pharmaceuticals Industries, Akorn (US), Catalent Pharma Solutions (US), Chongqing Huapont (China), Inc. (Israel), Dr. Reddy's Laboratories (India), Douglas Pharmaceuticals Ltd (New Zealand), F. Hoffmann La Roche (Europe)., Mylan (US), Cipher Pharmaceuticals (US), GlaxoSmithKline (UK), and Sun Pharmaceuticals (India).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE
  • 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF ACNE AMONG TEENS AND YOUNG ADULTS
    • 4.2.2 INCREASING INCIDENCE OF NEUROBLASTOMA
  • 4.3 RESTRAINT
    • 4.3.1 CONCERNS PERTAINING TO DRUG SIDE EFFECTS
  • 4.4 OPPORTUNITY
    • 4.4.1 INTRODUCTION OF NEW MICRONIZED FORMATION FOR SEVERE RECALCITRANT NODULAR ACNE TREATMENT

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION & SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON ISOTRETINOIN DRUGS MARKET
    • 5.3.1 IMPACT ON SUPPLY CHAIN
    • 5.3.2 IMPACT ON THE ISOTRETINOIN DRUGS MARKET
    • 5.3.3 IMPACT ON GDP AND HEALTHCARE EXPENDITURE
  • 5.4 OFF LABEL USAGE OF ISOTRETINOIN CAPSULES
  • 5.5 BY INDICAITION ANALYSIS ON PRESCRIBED PERSONNEL AND DOSAGE

6 GLOBAL ISOTRETINOIN DRUGS MARKET, BY FORM

  • 6.1 OVERVIEW
  • 6.2 CAPSULE
  • 6.3 INJECTION

7 GLOBAL ISOTRETINOIN DRUGS MARKET, BY INDICATION

  • 7.1 OVERVIEW
  • 7.2 SEVERE ACNE
  • 7.3 SQUAMOUS CELL CARCINOMA
  • 7.4 CUTANEOUS T-CELL LYMPHOMA
  • 7.5 NEUROBLASTOMA
  • 7.6 HARLEQUIN ICHTHYOSIS
  • 7.7 XERODERMA PIGMENTOSUM
  • 7.8 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
  • 7.9 OTHERS

8 GLOBAL ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 8.1 OVERVIEW
  • 8.2 HOSPITAL PHARMACIES
  • 8.3 RETAIL PHARMACIES
  • 8.4 ONLINE PHARMACIES

9 GLOBAL ISOTRETINOIN DRUGS MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 FRANCE
    • 9.3.3 UK
    • 9.3.4 ITALY
    • 9.3.5 RUSSIA
    • 9.3.6 SPAIN
    • 9.3.7 UKRAINE
    • 9.3.8 REST OF EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 INDIA
    • 9.4.3 JAPAN
    • 9.4.4 SOUTH KOREA
    • 9.4.5 AUSTRALIA
    • 9.4.6 REST OF ASIA-PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA
    • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE BENCHMARKING
  • 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
  • 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
  • 10.5 KEY DEVELOPMENT ANALYSIS
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
    • 10.6.2 EXPANSIONS
  • 10.7 FINANCIAL MATRIX
    • 10.7.1 SALES (USD MILLION), 2020
    • 10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020

11 COMPANY PROFILES

  • 11.1 DOUGLAS PHARMACEUTICALS LIMITED
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS/SERVICES OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS/SERVICES OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 AKORN OPERATING COMPANY LLC
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS/SERVICES OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 KEY STRATEGIES
  • 11.4 DR. REDDY'S LABORATORIES LTD
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS/SERVICES OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 F. HOFFMAN LA ROCHE LTD
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS/SERVICES OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 SWOT ANALYSIS
    • 11.5.6 KEY STRATEGIES
  • 11.6 MYLAN NV
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS/SERVICES OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 KEY STRATEGIES
  • 11.7 SUN PHARMACEUTICALS
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 SWOT ANALYSIS
    • 11.7.6 KEY STRATEGIES
  • 11.8 CIPHER PHARMACEUTICALS INC.
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL ANALYSIS
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 KEY STRATEGIES
  • 11.9 GLAXOSMITHKLINE PLC
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL ANALYSIS
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 SWOT ANALYSIS
    • 11.9.6 KEY STRATEGIES
  • 11.10 CHONGQING HUAPONT
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL ANALYSIS
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 KEY STRATEGIES
  • 11.11 CATALENT PHARMA SOLUTIONS
    • 11.11.1 COMPANY OVERVIEW
    • 11.11.2 FINANCIAL ANALYSIS
    • 11.11.3 PRODUCTS OFFERED
    • 11.11.4 KEY DEVELOPMENTS
    • 11.11.5 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS